|View printer-friendly version|
Spring Bank Pharmaceuticals Announces Additional Inarigivir (formerly SB 9200) Results from the ACHIEVE Trial in HBV Patients at AASLD Conference
Inarigivir Phase 2 results confirm antiviral activity & novel mechanism of action
Data Safety Monitoring Board approves proceeding with enrollment of third cohort (inarigivir 100mg) of the ACHIEVE trial
In the first presentation, Professor
“The results from this first cohort demonstrate the promise and potency of inarigivir as a novel antiviral and immunomodulatory agent for the treatment of chronic HBV as we strive for a functional cure in our patients,” said Professor Yuen.
In the second presentation, a late-breaker poster presentation, Professor
“The dramatic reductions in HBV RNA and HBcrAg and associated changes in key epitopes of HBsAg point to a significant and novel antiviral effect of low dose inarigivir on key HBV functions, including pgRNA encapsidation and potentially the transcriptional activity of cccDNA,” said Professor Locarnini.
Following these presentations, a copy of presentation materials can be accessed by visiting the Investors & Media section of the company’s website at www.springbankpharm.com.
The ACHIEVE Trial
For investor inquires:
Source: Spring Bank Pharmaceuticals, Inc.